ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

July 25, 2014

Monica Bertagnolli To Succeed Schilsky As CALGB Chairman.

November 21, 2008

Final Regulations For Clinical Cancer Education Program Adopted

October 3, 1975

New Concepts Being Developed By Organ Systems Groups Described

January 2, 1987

AACI Committee Makes Case For Clinical Research In Centers; Cancer Control, Group Funds Eyed

December 8, 1978

Genentech Says Phase III Trial Shows Avastin Improved PFS For Ovarian Cancer

March 26, 2010